Scholarlink

<p>In a carcinogenicity study with CD-1 mice exposed to pyridachlometyl (dietary dose levels: 0, 700, 2000, and 7000&#xa0;ppm), a combined incidence of hepatocellular adenoma and carcinoma was increased in male mice at doses ≥ 2000&#xa0;ppm, but not in female mice. We evaluated the mode of action (MOA) of pyridachlometyl-induced liver tumor formation in male mice and its relevance to humans. Pyridachlometyl was found to be neither genotoxic, cytotoxic, immunosuppressive, nor hormone-mediated based on a series of toxicity studies. Data from general toxicity studies suggested that the MOA involves activation of the nuclear receptor constitutive androstane receptor (CAR), leading to a pleiotropic response including altered gene expression specific to CAR activation, increased hepatocyte proliferation, clonal expansion resulting in altered hepatic foci, and ultimately liver tumor formation. Short-term in vivo MOA studies in CD-1 mice showed that pyridachlometyl significantly increased liver weight, incidence of centrilobular hepatocyte hypertrophy, <i>Cyp2b10</i> and <i>Cyp3a11</i> mRNA levels and their enzyme activities, and hepatocyte replicative DNA synthesis, all in a dose-dependent manner. These effects were reversible upon cessation of treatment and were attenuated in CAR/PXR knockout mice. Pyridachlometyl induced human <i>CYP2B6</i> and <i>CYP3A4</i> mRNAs but did not increase replicative DNA synthesis in either cultured human hepatocytes or human hepatocytes in chimeric mice (PXB-mice). Overall, these data strongly support that the MOA for pyridachlometyl-induced hepatocellular tumors in male mice is via activation of CAR, indicatiing that the liver tumor formation observed in male mice is not relevant to humans.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

  • 期刊论文

  • 发表日期：

    2025年6月9日

查看全文
  • Kensuke Kawamoto,
  • Yukako Shimotsuma,
  • Keiko Maeda,
  • Kohei Matsunaga,
  • Hiroyuki Asano,
  • Samuel M. Cohen,
  • Tomoya Yamada

摘要

In a carcinogenicity study with CD-1 mice exposed to pyridachlometyl (dietary dose levels: 0, 700, 2000, and 7000 ppm), a combined incidence of hepatocellular adenoma and carcinoma was increased in male mice at doses ≥ 2000 ppm, but not in female mice. We evaluated the mode of action (MOA) of pyridachlometyl-induced liver tumor formation in male mice and its relevance to humans. Pyridachlometyl was found to be neither genotoxic, cytotoxic, immunosuppressive, nor hormone-mediated based on a series of toxicity studies. Data from general toxicity studies suggested that the MOA involves activation of the nuclear receptor constitutive androstane receptor (CAR), leading to a pleiotropic response including altered gene expression specific to CAR activation, increased hepatocyte proliferation, clonal expansion resulting in altered hepatic foci, and ultimately liver tumor formation. Short-term in vivo MOA studies in CD-1 mice showed that pyridachlometyl significantly increased liver weight, incidence of centrilobular hepatocyte hypertrophy, Cyp2b10 and Cyp3a11 mRNA levels and their enzyme activities, and hepatocyte replicative DNA synthesis, all in a dose-dependent manner. These effects were reversible upon cessation of treatment and were attenuated in CAR/PXR knockout mice. Pyridachlometyl induced human CYP2B6 and CYP3A4 mRNAs but did not increase replicative DNA synthesis in either cultured human hepatocytes or human hepatocytes in chimeric mice (PXB-mice). Overall, these data strongly support that the MOA for pyridachlometyl-induced hepatocellular tumors in male mice is via activation of CAR, indicatiing that the liver tumor formation observed in male mice is not relevant to humans.